Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lewit, N.
Right arrow Articles by Itskovitz-Eldor, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewit, N.
Right arrow Articles by Itskovitz-Eldor, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. 7, pp. 1399-1402, 1996
© 1996 European Society of Human Reproduction and Embryology

research-article

Endocrinology: Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study

N. Lewit, S. Kol1, D. Manor and J. Itskovitz-Eldor

Department of Obstetncs and Gynecology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology Haifa 31096, Israel

Correspondence: 1To whom correspondence should be addressed

Gonadotrophin-releasing hormone analogue (GnRHa) has been suggested as an alternative to human chorionic gonadotrophin (HCG) for triggering ovulation, while preventing ovarian hyperstimulation syndrome (OHSS). Since a prospective, controlled study would be unethical at this point, we used a retrospective, case-self control approach to compare GnRHa with HCG in that context. A group of 16 in-vitro fertilization (IVF) patients who had severe OHSS in previous cycles, in which HCG was given to trigger ovulation, were studied in subsequent cycles in which GnRHa was used. Each GnRHa cycle (case) was compared to a previous HCG cycle that resulted in OHSS (self control). None of these subsequent cydes resulted in severe OHSS. The use of GnRHa did not affect the number of oocytes retrieved or their quality. Serum oestradiol concentrations on the day of ovulation triggering were signilicantly (P<0.01) higher in the GnRHa cycles compared to HCG cycles. Exogenous progesterone and oestra diol were effective in maintaining relatively constant serum oestradiol and progesterone serum concentrations during the luteal phase. Pregnancy rate per cycle was similar in the two groups. In conclusion, the use of GnRHa to induce ovulation in IVF patients, who are at high risk for developing OHSS, effectively eliminates this risk without affecting other parameters of the stimulation cycle.

Key words: GnRH analogue/HCG/IVF-embryo transfer/ovarian hyperstimulation syndrome/ovulation induction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva
Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial
Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
G. Griesinger, K. Diedrich, P. Devroey, and E.M. Kolibianakis
GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis
Hum. Reprod. Update, March 1, 2006; 12(2): 159 - 168.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. Engmann and C. Benadiva
GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study
Hum. Reprod., November 1, 2005; 20(11): 3258 - 3260.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Endo, H. Honnma, T. Hayashi, M. Chida, K. Yamazaki, Y. Kitajima, A. Azumaguchi, H. Kamiya, and R. Kudo
Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos
Hum. Reprod., October 1, 2002; 17(10): 2548 - 2551.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Kol and J. Itskovitz-Eldor
Severe OHSS: Yes, there is a strategy to prevent it!
Hum. Reprod., November 1, 2000; 15(11): 2266 - 2267.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P.E. Egbase, M.A. Sharhan, P. Berlingieri, and J.G. Grudzinskas
Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment
Hum. Reprod., October 1, 2000; 15(10): 2082 - 2086.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Itskovitz-Eldor, S. Kol, and B. Mannaerts
Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication
Hum. Reprod., September 1, 2000; 15(9): 1965 - 1968.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.